Emerging Systemic Therapies for the Management of Penile Cancer

Shilpa Gupta; Guru Sonpavde

doi:10.1016/j.ucl.2016.06.009

Emerging Systemic Therapies for the Management of Penile Cancer

Urol Clin North Am. 2016 Nov;43(4):481-491. doi: 10.1016/j.ucl.2016.06.009. Epub 2016 Sep 3.

Authors

Shilpa Gupta¹, Guru Sonpavde²

Affiliations

¹ Department of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA.
² Section of Medical Oncology, Department of Medicine, UAB Comprehensive Cancer Center, 1802 6th Avenue South, NP2540B, Birmingham, AL 35294, USA. Electronic address: gsonpavde@uabmc.edu.

PMID: 27717434
DOI: 10.1016/j.ucl.2016.06.009

Abstract

Penile squamous cell carcinoma (PSCC) is a rare cancer, but is more common in developing countries. Locally advanced and metastatic PSCC is associated with significant morbidity and mortality, with the prognosis remaining extremely poor. The authors searched PubMed and published abstracts for metastatic PSCC studies to describe emerging therapies. Multimodality treatment using chemotherapy, radiation, and consolidative surgery are standard of care. Utilizing anti-EGFR therapies and novel immunotheraputic approaches may help improve outcomes in PSCC.

Keywords: Chemotherapy; Combined modality therapy; EGFR; PD-1; Penile squamous cell carcinoma; Targeted therapy; VEGF.

Publication types

Review

MeSH terms

Carcinoma, Squamous Cell / diagnosis
Carcinoma, Squamous Cell / therapy*
Combined Modality Therapy
Disease Management*
Humans
Male
Penile Neoplasms / diagnosis
Penile Neoplasms / therapy*
Prognosis